305  0 Kommentare Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360 Blood Test for Comprehensive Genomic Profiling

“We are pleased that these major health insurers have taken this step to improve access to comprehensive genomic profiling for their patients with advanced cancers,” said Helmy Eltoukhy, Guardant Health co-CEO. “The Guardant360 blood test can help oncologists quickly identify the specific mutations driving cancer in order to select the most appropriate therapy. We believe this recognition of the clinical value of our test will result in improved outcomes for more patients with cancer.”

In February, Guardant Health announced that it had received coverage from UnitedHealthcare for Guardant360 CDx as companion diagnostic in advanced lung and breast cancer. Over the past few weeks, the Guardant360 test has received commercial policy coverage from three additional major U.S. health insurers.

The Guardant360 test received coverage under Anthem Blue Cross and Blue Shield commercial health insurance policies for complete genomic profiling of any solid tumor to identify actionable biomarkers to inform therapy selection. Anthem operates in 14 states and provides 32 million individuals with access to more than 1.7 million doctors and hospitals nationwide through Anthem brands and the greater Blue Cross Blue Shield network.

In addition, Aetna confirmed commercial coverage of the Guardant360 CDx test as a companion diagnostic to identify estrogen receptor 1 (ESR1) gene mutations in persons with advanced breast cancer being considered for treatment with ORSERDU (elacestrant).

The Guardant360 CDx test also received commercial medical policy coverage from Humana for use as a companion diagnostic to identify individuals diagnosed with advanced or metastatic, ER-positive, HER2-negative breast cancer whose disease progressed following at least one line of endocrine therapy and are eligible for treatment with ORSERDU (elacestrant).